Medpace (MEDP) 10-Q2024 Q1 Quarterly report

Filed: 23 Apr 24, 4:02pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Avg

New words: absence, Ashley, ASU, Burwig, FASB, February, firm, Geiger, Good, hope, Jesse, Keating, opportunity, outlook, permitted, recent, recovery, reduced, replace, segment, standard, statement, Susan, Topic, transaction, trend, uncategorized, Vice, wide

Removed: affiliate, anniversary, approach, continuing, longer, meeting, preceding, scheduled, traded, vest

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MEDP transcripts

MEDP similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO SECTION 906

OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Medpace Holdings, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2024 filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

•The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company for the periods presented therein.

Date: April 23, 2024


			By:			/s/ August J. Troendle
						August J. Troendle
						Chief Executive Officer and Chairman of the Board of Directors
						(Principal Executive Officer)

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.